{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=118", "query": { "intervention": "serum sample", "page": 118 }, "page_size": 10 }, "pagination": { "page": 118, "page_size": 10, "total_count": 8384, "total_pages": 839, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=119&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=117&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T23:46:36.189Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02508077", "title": "FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Colorectal Carcinoma", "Stage IVA Colorectal Cancer", "Stage IVB Colorectal Cancer" ], "interventions": [ { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Panitumumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2016-02-16", "completion_date": "2017-09-13", "has_results": true, "last_update_posted_date": "2018-08-16", "last_synced_at": "2026-11-11T23:46:36.189Z", "location_count": 4, "location_summary": "Duarte, California • Lancaster, California • Rancho Cucamonga, California + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Rancho Cucamonga", "state": "California" }, { "city": "South Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02508077" }, { "nct_id": "NCT01040819", "title": "Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Pioglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 25, "start_date": "2010-02", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2016-06-22", "last_synced_at": "2026-11-11T23:46:36.189Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01040819" }, { "nct_id": "NCT00559702", "title": "Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsing-Remitting Multiple Sclerosis", "Secondary Progressive Multiple Sclerosis" ], "interventions": [ { "name": "natalizumab", "type": "DRUG" }, { "name": "standard of care", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 76, "start_date": "2007-10", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2014-09-09", "last_synced_at": "2026-11-11T23:46:36.189Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Maitland", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00559702" }, { "nct_id": "NCT00453102", "title": "Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Marginal Zone Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Ibritumomab Tiuxetan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 18, "start_date": "2006-02", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2016-01-01", "last_synced_at": "2026-11-11T23:46:36.189Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00453102" }, { "nct_id": "NCT06109272", "title": "A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Livmoniplimab", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2024-01-11", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-11-11T23:46:36.189Z", "location_count": 13, "location_summary": "Duarte, California • Irvine, California • Orange, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Merriam", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06109272" }, { "nct_id": "NCT01070303", "title": "Remission in Subjects With Crohn's Disease, Open Label Extension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Adalimumab 40 mg eow or ew", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 177, "start_date": "2002-08", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2011-04-11", "last_synced_at": "2026-11-11T23:46:36.189Z", "location_count": 43, "location_summary": "Berkeley, California • Long Beach, California • San Diego, California + 36 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Bridgeport", "state": "Connecticut" }, { "city": "Weston", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01070303" }, { "nct_id": "NCT06060873", "title": "MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Malignant Testicular Germ Cell Tumor" ], "interventions": [ { "name": "Clinical Stage I Disease", "type": "OTHER" }, { "name": "Clinical Stage I with relapse, CSII Disease", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 418, "start_date": "2023-06-08", "completion_date": "2028-12-08", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-11-11T23:46:36.189Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06060873" }, { "nct_id": "NCT00831675", "title": "Study of Safety and Immunogenicity of Fluzone® in Healthy Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Influenza Vaccine 2004-2005 Paediatric Formulation", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Months", "maximum_age": "35 Months", "sex": "ALL", "summary": "6 Months to 35 Months" }, "enrollment_count": 30, "start_date": "2004-09", "completion_date": "2006-04", "has_results": true, "last_update_posted_date": "2016-04-14", "last_synced_at": "2026-11-11T23:46:36.189Z", "location_count": 1, "location_summary": "Norfolk, Virginia", "locations": [ { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00831675" }, { "nct_id": "NCT06824454", "title": "Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypophosphatemia", "Kidney Transplantation" ], "interventions": [ { "name": "Dipyridamole 75 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2025-05-15", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-11-11T23:46:36.189Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06824454" }, { "nct_id": "NCT00410605", "title": "Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma in Relapse", "Stage II Multiple Myeloma", "Stage III Multiple Myeloma" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "lenalidomide", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2006-11", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2017-09-01", "last_synced_at": "2026-11-11T23:46:36.189Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania • Madison, Wisconsin", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00410605" } ] }